STOCK TITAN

Mirum Pharmaceuticals Inc - MIRM STOCK NEWS

Welcome to our dedicated news page for Mirum Pharmaceuticals (Ticker: MIRM), a resource for investors and traders seeking the latest updates and insights on Mirum Pharmaceuticals.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Mirum Pharmaceuticals's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Mirum Pharmaceuticals's position in the market.

Rhea-AI Summary
Mirum Pharmaceuticals grants inducement awards to new employees
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
none
-
Rhea-AI Summary
Mirum Pharmaceuticals, Inc. to participate in upcoming investor conferences
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3.22%
Tags
conferences
-
Rhea-AI Summary
Mirum acquires Travere's rights and assets for Cholbam® and Chenodal®, paying $210 million upfront with potential for $235 million in milestone payments. Expands Mirum's rare liver disease portfolio and strengthens Travere's financial foundation.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
4.46%
Tags
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.87%
Tags
none
-
Rhea-AI Summary
Mirum Pharmaceuticals, Inc. (Nasdaq: MIRM) reported $37.5 million total revenue for Q2 2023, including $32.5 million net product sales for LIVMARLI. The company is acquiring CHENODAL® and CHOLBAM®, and expects four late-stage clinical trial data readouts later this year. The PR highlights the financial results, business updates, and future catalysts.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
6.31%
Tags
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.94%
Tags
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.29%
Tags
none
-
Rhea-AI Summary
Mirum Pharmaceuticals and Travere Therapeutics have entered into a definitive agreement for the sale of Travere's bile acid product portfolio. Mirum will acquire Travere's rights to Cholbam® and Chenodal® for $445 million, with $210 million upfront and up to $235 million in potential sales-based milestones. Mirum has secured $210 million in funding to finance the upfront payment. The transaction is expected to close in Q3 2023.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3.39%
Tags
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.38%
Tags
none
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-4.24%
Tags
none
Mirum Pharmaceuticals Inc

Nasdaq:MIRM

MIRM Rankings

MIRM Stock Data

1.16B
35.19M
2.25%
112.23%
17.36%
Research and Development in Biotechnology
Professional, Scientific, and Technical Services
Link
United States
Foster City

About MIRM

mirum pharmaceuticals, inc., a biopharmaceutical company, focuses on the development and commercialization of a late-stage pipeline of novel therapies for debilitating liver diseases. its lead product candidate is maralixibat, an investigational oral drug that is in phase 3 clinical trial for the treatment of progressive familial intrahepatic cholestasis disease, as well as for the treatment of alagille syndrome and biliary atresia disease. the company is also develops volixibat drug for treatment of intrahepatic cholestasis of pregnancy and primary sclerosing cholangitis. mirum pharmaceuticals, inc. was founded in 2018 and is headquartered in foster city, california.